CTOR — Citius Oncology Income Statement
0.000.00%
Last trade - 00:00- $52.16m
- $55.96m
Annual income statement for Citius Oncology, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 September 30th | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 0.01 | 0.138 | 1.01 | 20.6 |
| Operating Profit | -0.01 | -0.138 | -1.01 | -20.6 |
| Total Net Non Operating Interest Income / Expense | ||||
| Net Income Before Taxes | -0.01 | 0.381 | 2.42 | -20.6 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -0.01 | 0.381 | 2.42 | -21.1 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -0.01 | 0.381 | 2.42 | -21.1 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -0.01 | 0.381 | 2.42 | -21.1 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.001 | 0.042 | 0.27 | -0.311 |
| Dividends per Share |